Author

A. Garcia-Gomez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:chromatin & epigenetic regulation· 2 Assay:DNA methylation· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

E. Ballestar· 2 shared F. Catala-Moll· 2 shared L. Ciudad· 2 shared A. Ruiz-Sanmartin· 1 shared C. Lorente-Sorolla· 1 shared C. Ortiz de Solorzano· 1 shared D. Alvarez-Errico· 1 shared E. San Jose-Eneriz· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. Ballestar

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The JAK2-STAT pathway epigenetically regulates tolerized genes during the first encounter with bacterial antigens

C. Lorente-Sorolla, O. Morante-Palacios, A. Garcia-Gomez, L. Ciudad, F. Catala-Moll, A. Ruiz-Sanmartin, M. Martinez-Gallo, R. Ferrer-Roca, J. C. Ruiz-Rodriguez, D. Alvarez-Errico, E. Ballestar

The paper identifies JAK2-STAT pathway involvement in epigenetic regulation of tolerized genes during first bacterial antigen exposure, showing its role in modulating inflammatory responses.

bioRxiv · Oct 16, 2020 · PreprintImmunology

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

A. Garcia-Gomez, T. Li, J. Rodriguez-Ubreva, L. Ciudad, F. Catala-Moll, M. Martin, L. San-Segundo, X. Morales, C. Ortiz de Solorzano, J. Oyarzabal, E. San Jose-Eneriz, X. Agirre, F. Prosper, M. Garayoa, E. Ballestar

This study identifies aberrant DNA methylation in mesenchymal stromal cells from myeloma patients and shows that targeting DNMTs and G9a with CM-272 reverses bone loss and reduces tumor burden.

bioRxiv · Sep 12, 2019Cancer Biology